Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial ...

The Pharma stocks are seeing big cuts in early trade. The Nifty Pharma Index is down over 1% and the BSE Healthcare Index too remains under pressure. Some of the big Nifty losers include the likes ...

For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the ...

A fresh threat by US president Donald Trump on Monday that sector-specific tariffs on pharmaceuticals could be announced in the next two weeks has hammered the stocks of Indian drug-makers on ...

The pharma industry’s reputation has continued to slide — and it’s mostly due to the persistent issue of high drug costs, according to a report released by research firm PatientView this week.

President Donald Trump signaled that he plans to announce new tariffs on pharmaceutical products imported to the United States “over the next two weeks.” Trump’s overriding tariff agenda has ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than ...

Sun Pharma shares sell off on lower US revenue and modest FY26 growth outlook: Should you Buy, Hold, or Sell? May 23 2025 09:44 AM Stocks to Watch Today: ITC, Sun Pharma, IndusInd Bank ...

In his 42-year journey of building Sun Pharma from the ground up, there is only one thing Dilip Shanghvi would do differently. “Sometimes I would have got angry… That I wouldn’t have wanted ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...

(Reuters) -Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter.